Bicocca Open Archive

Logo unimib boa
CAIROLI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.003
AS - Asia 2.095
NA - Nord America 1.874
SA - Sud America 49
AF - Africa 17
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.048
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.838
IE - Irlanda 896
HK - Hong Kong 872
RU - Federazione Russa 802
IT - Italia 779
SG - Singapore 775
CN - Cina 256
DE - Germania 115
GB - Regno Unito 98
SE - Svezia 83
ID - Indonesia 58
FI - Finlandia 53
IN - India 51
BR - Brasile 38
ES - Italia 35
NL - Olanda 30
UA - Ucraina 21
FR - Francia 20
CA - Canada 19
JP - Giappone 17
MX - Messico 16
CH - Svizzera 13
VN - Vietnam 11
BE - Belgio 10
TR - Turchia 10
AU - Australia 8
DK - Danimarca 8
SA - Arabia Saudita 8
HR - Croazia 7
HU - Ungheria 7
GR - Grecia 6
PL - Polonia 6
CL - Cile 5
CO - Colombia 5
IL - Israele 5
IR - Iran 5
NP - Nepal 5
CZ - Repubblica Ceca 4
MA - Marocco 4
PH - Filippine 4
RO - Romania 4
TH - Thailandia 4
EG - Egitto 3
KR - Corea 3
PK - Pakistan 3
TN - Tunisia 3
TW - Taiwan 3
ZA - Sudafrica 3
AM - Armenia 2
SI - Slovenia 2
UG - Uganda 2
AR - Argentina 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CR - Costa Rica 1
CY - Cipro 1
EU - Europa 1
GH - Ghana 1
JO - Giordania 1
LV - Lettonia 1
LY - Libia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 7.048
Salva come PNG Salva come JPEG
Città #
Hong Kong 868
Dublin 845
Singapore 684
New York 390
Santa Clara 209
Milan 201
Ashburn 182
Ann Arbor 124
Beijing 112
Turin 84
Frankfurt am Main 73
Jakarta 54
Shanghai 48
Fairfield 46
Seattle 43
Chandler 41
Desio 40
Helsinki 37
Boardman 34
Rome 34
London 31
São Paulo 26
Washington 25
Amsterdam 22
Houston 22
Los Angeles 22
Jacksonville 19
Princeton 18
Wilmington 18
Kilburn 17
Assago 16
Dearborn 16
Madrid 14
Bologna 13
Cambridge 13
Cinisello Balsamo 13
Lappeenranta 13
Phoenix 13
Woodbridge 13
Guadalajara 11
Mumbai 11
Nanjing 10
Naples 10
Altamura 9
Aurora 9
Lawrence 9
San Diego 9
Carate Brianza 8
Chiswick 8
Moscow 8
Brussels 7
Debrecen 7
Hyderabad 7
Orbassano 7
Zagreb 7
Changsha 6
Santa Monica 6
Brescia 5
Brugherio 5
Chengdu 5
Corsico 5
Dallas 5
Istanbul 5
Melzo 5
Palermo 5
Paris 5
Rocca Canavese 5
San Jose 5
Taiyuan 5
Tel Aviv 5
Veniano 5
Verona 5
Bari 4
Biratnagar 4
Delhi 4
Genoa 4
Guangzhou 4
Hangzhou 4
Kolkata 4
Montreal 4
Monza 4
Munich 4
Nuremberg 4
Ottawa 4
Padova 4
Perugia 4
Shijiazhuang 4
Toronto 4
Torre Annunziata 4
Aalst 3
Abbiategrasso 3
Alatri 3
Americana 3
Arezzo 3
Asahikawa 3
Barcelona 3
Beauharnois 3
Bergamo 3
Burlington 3
Cantu 3
Totale 4.818
Salva come PNG Salva come JPEG
Nome #
Assessing eligibility for treatment in acute myeloid leukemia in 2023 242
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 194
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 152
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia 147
The role of quantitative polymerase chain reaction in the management of follicular lymphoma patients 129
Impact of serial echocardiography in the management of primary cardiac lymphoma 125
KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication 106
Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review 81
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 77
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 61
Use of Sorafenib in FLT3-Mutant Myeloid Sarcoma: A Case Report 57
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities 54
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 51
MIS-A: Beware of non-lymphoma 47
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 46
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 45
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 42
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective? 42
"Efficient Strategies for the Reuse of Surgical and FFP2/ KN95 Face Masks during the COVID-19 Pandemic: Home-Made and Ecological Choices for the Community" 41
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial 41
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 41
A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms 40
IN ADULT ACUTE MYELOID LEUKEMIA (AML) PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY (FC) IS FEASIBLE AND IS PROGNOSTICALLY RELEVANT 39
Arg expression studied in normal human leukocytes and in leukemic cells by RT-PCR 39
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management 38
Cordycepin (3′dA) Induces Cell Death of AC133+ Leukemia Cells via Re-Expression of WIF1 and Down-Modulation of MYC 38
A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML 37
Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT 36
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: Results of an Italian multicenter study 36
c-kit activating mutations and mast cell proliferation in human leukemia [4] 36
Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study 35
Fungal infections in hematologic neoplasms: Autopsy findings 35
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy 35
Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization 35
Intrahospital COVID-19 infection outbreak management: Keep calm and carry on 35
Detection by polymerase chain reaction of BCR/ ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation 34
C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index 34
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 33
ACUTE PROMYELOCYTIC LEUKEMIA - COMPLETE REMISSION AND BONE-MARROW TRANSPLANTATION FOLLOW-UP MONITORED BY POLYMERASE CHAIN-REACTION 33
A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis 33
Treatment of elderly patients with acute promyelocytic leukemia: A real life experience of the “rete ematologica lombarda” 33
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 32
CLINICAL RELEVANCE OF RECURRENT ALLELE-SPECIFIC RECOMBINATION EXPRESSING THE WNT10BIVS1 ALLELE VARIANT IN ACUTE MYELOID LEUKEMIA 32
A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis 31
Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL) 31
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 30
Myeloma’s multiple morphologies 30
Advances in the understanding of molecular genetics and therapy ofRichter transformation in chronic lymphocytic leukemia 30
Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects 30
Gastrointestinal Kaposi's Sarcoma in a Woman with Selective IgA Deficiency and prior Immunosuppressive therapy for Idiopathic Thrombocitopenioc Purpura 30
Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients 30
Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases 30
Prognostic significance of CD33, CD34 and CD117 expression on bone marrow blasts of patients with Myelodysplastic syndromes 30
Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection 30
LABNET AML: AN EFFICIENT NETWORK THAT CONNECTS HEMATOLOGY CENTERS AND LABORATORIES FOR A HIGH-LEVEL DIAGNOSTIC/PROGNOSTIC WORKUP OF AML 30
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 29
Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles 29
Use of Plerixafor in Poor Mobilizer Patients with Myeloma and Lymphoma: Clonogenic Capacity and Engraftment Data 29
Detection of c-KIT antigen (CD117) and c-kit mRNA in acute leukemia 29
Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy) 29
Correction to: Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial (Experimental Hematology & Oncology, (2021), 10, 1, (14), 10.1186/s40164-021-00210-9) 29
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial 28
RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP 28
PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation 28
Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience 28
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study 28
Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era 28
PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS 27
Ibrutinib and its use in the treatment o chronic lymphocytic leukemia 27
Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment 27
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19 27
Lymphoma’s last therapeutic option: Freeze it! 27
High dose etoposide and cyclophosphamide (HD-VP/CTX) as salvage treatment for all patients 27
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 26
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 26
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma 26
Prospective clinical study on extracorporeal photopheresis (ECP) as prophylaxis for chronic Graft Versus Host Disease (cGVHD) prophylaxis: an interim analysis 26
Plasma cell-directed therapy and anti-HLA antibody production: A successful combination? 26
SEVERE HIV-RELATED THROMBOCYTOPENIA (HIV-REL TP) - COULD SPLENECTOMY IMPROVE SURVIVAL 26
Flow cytometry analysis of lymphocyte subsets in bronchoalveolar lavage: comparison between lung non-Hodgkin lymphomas and reactive diseases 26
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS 25
A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting 25
Duvelisib: A new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia 25
Quantification of BCR/ABL transcript in mobilized cells of CML patients 25
Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H 25
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation 25
Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial 25
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience 24
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 24
Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia 24
Complications at insertion of untunnelled central venous catheters (UCVCs) in leukemic patients at a high risk of hemorrhage 24
Prevalence and prognostic impact of KIT mutations in acute myeloid leukaemia with INV(16) 24
Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens 24
Hypoplasia of the Spleen: Rare and Puzzling 24
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study 24
Limited feasibility of double transplant program: A multicenter study on 151 multiple myeloma patients aged <= 65 years 24
Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta 24
Total serum tryptase: a predictive marker for KIT mutation in acute myeloid leukemia 24
ABNORMALITIES OF RED-BLOOD-CELLS (RBC) CYTOSKELETAL PROTEINS AND OF PLATELET (PLT) VON-WILLEBRAND-FACTOR (VWF) IN THE MYELODYSPLASTIC SYNDROMES (MDS 24
Is Ashwell-Morell Receptor Mediated Hepatic Clearance of Platelet Clinically Relevant in Immune Thrombocytopenia (ITP)? a Retrospective Analysis of Platelet Kinetic Studies and Autoantibody Type Data 24
Totale 4.134
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.526
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.526
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202073 0 0 0 9 9 16 13 7 8 4 4 3
2020/2021141 3 3 40 14 15 11 12 12 14 6 3 8
2021/2022121 6 3 15 7 11 10 2 14 7 8 12 26
2022/20231.417 27 57 11 13 9 26 0 151 58 921 64 80
2023/20243.794 57 115 139 106 515 840 653 200 657 104 76 332
2024/20252.323 545 1.184 457 137 0 0 0 0 0 0 0 0
Totale 8.006